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two different quarters between 01/01/2006 and 12/31/2008. A patient was consid-
ered to have had new onset T2DM in 2008 under one of three conditions; firstly,
he/she had not received a diagnosis of T2DM in 2006 and 2007; secondly, had not
received oral anti-diabetics in 2006/2007; and thirdly, had received either one in-
patient or two outpatient T2DM diagnosis in 2008. RESULTS: In our sample, a total
of 254,523 patients had T2DM. The prevalence of T2DMwas 4.69 % (women: 3.26%;
men: 6.03%). The average age of these T2DM patients was 64.8 years, and 66.4%
weremale. The incidence of T2DM in our sample was 4.889 cases per 1,000 person-
years in men and 2.863 cases in 1,000 person-years in women. T2DM prevalence/
incidence strongly depended on gender and age. Whereas the T2DM prevalence in
both men and women was below 0.9% in all age groups 40 years, it increased up
to 25.17% (men)/24.34% (women) in the second-highest age group, 85-90 years.
CONCLUSIONS:A comparison of the distribution of AF prevalence/incidence in our
population with that in already published studies shows that our figures are com-
paratively high. Obviously, in a large industrial nation such as Germany, care pro-
vision structures are going to be challenged by the requirement to treatmore T2DM
patients in the future.
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OBJECTIVES: Previous research has shown patients with diabetes have a higher
risk of death following pneumonia. This study examined the impact of diabetes
diagnosis on in-hospital mortality and length of stay in the inpatient setting.
METHODS: MedAssets health system data (October 2010 to September 2011) were
analyzed for adult inpatients with a principle diagnosis of community-acquired
pneumonia. Cohorts of patientswith andwithout type 2-diabeteswerematched on
age and sex using a propensity score and Greedy matching algorithm. In-hospital
mortality and length of stay were compared between cohorts using multivariate
logistic and negative binomial regression models, respectively, controlling for age,
gender, admission source and type, ventilator use, Deyo-Charlson comorbidity
score, hospital bed size, region, and teaching status. RESULTS: Of 282,474 patients
with pneumonia, approximately 19% had diabetes. Matching resulted in 34,999
patients in each cohort with a mean age of 69 and proportionately more females
than males (51.8% vs. 47.9%). Diabetic patients had higher Deyo-Charlson scores
(3.14 vs. 2.49, p 0.0001) and higher rates of ventilator use (14.1% vs. 10.3%, p
0.0001). Patients diagnosed with diabetes were 26% less likely to die during hospi-
talization (OR  0.74, CI  0.68-0.80). Diabetic patients had a 2% longer length of
stay (IRR  1.02, CI  1.01-1.04). CONCLUSIONS: After controlling for other vari-
ables, patients with type-2 diabetes had a lower risk of in-hospital mortality and
longer length of stay when hospitalized for pneumonia compared to patients with-
out diabetes. Glucose levels at the time of admission and history of diagnosis may
explain some of the association, while care of diabetic patients and residual ben-
efits of other treatments may have reduced the risk of in-inpatient mortality. Fur-
ther studies should assess post-hospitalization outcomes.
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OBJECTIVES: To determine which factors were associated with sustained poor or
good glycemic control over three years. METHODS: This retrospective study of
enrollees in a large health plan in Hawaii with diabeteswas restricted to thosewith
poor control at baseline (HbA1c9% in the year 2006), who had HbA1c values for
four years (2006-2009, n2970). Separate multivariable logistic regressions exam-
ined factors related to poor (HbA1c9%) or good (HbA1c7%) control over three
years. Independent variables included age, gender, island of residence, type of
coverage, comorbid conditions, diabetes duration, and number of medications.
RESULTS: Relative to patientswith diabetes duration of a year or less, patientswith
diabetes for8 yearswere significantly less likely to sustain good control [OR0.13,
95%CI(0.09, 0.21)], as were patients with diabetes for 6-7 years [OR0.23,
95%CI(0.13, 0.39)], and 4-5 years [OR0.17, 95%CI(0.09, 0.31)]. Compared to patients
in HMO, patients in PPO or Medicare cost contract were significantly more likely to
have good control. Factors significantly related to poor control were age, diabetes
duration, morbidity level, and number of medications. Relative to patients aged
50-64, younger patients were significantlymore likely to have poor control [age35
OR1.98, 95%CI(1.25, 3.14); age 35-49 OR 1.27, 95%CI(1.03, 1.57)] and older patients
were significantly less likely [age 65-79 OR0.75, 95%CI(0.57, 0.98); age 80
OR0.63, 95%CI (0.41, 0.97)]. Longer diabetes duration and higher morbidity in-
creased the risk of poor control, while patients taking 15medications decreased
the risk. CONCLUSIONS: As diabetes duration strongly predicted poor control, pri-
mary prevention to decrease early onset of diabetes might be a cost-effective
means to reduce the number of patients with poor control. Our findings that
younger patients with diabetes are most likely to have poor control suggest that
interventions need to be targeted to this population.
DIABETES/ENDOCRINE DISORDERS – Cost Studies
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OBJECTIVES: Diabetes mellitus is a syndrome characterized by chronic hypergly-
cemia with absolute or relative deficiencies of insulin and/or in its action. The
National Health System (SUS), through the pharmaceutical assistancemust ensure
medications and supplies needed for the monitoring of capillary blood glucose of
diabetic patients, defined byministerial decree. The aim of this study is to evaluate
the financial impact of inputs for monitoring capillary blood glucose in relation to
medicinal products for treatment of diabetes mellitus in the state of Minas Gerais
in 2011. METHODS: Survey distribution and financial cost through the computer-
ized management of pharmaceutical assistance (SIGAF) in thez State of Minas
Gerais in 2011 of oral antidiabetics (glibenclamide 5 mg andmetformin hydrochlo-
ride 850mg), human insulinNPHand regular human insulin and indicator strip that
measures the glucose.RESULTS:The costs for regular andNPH Insulin in 2011were
U$8.320.793,31, with oral antidiabetic agents was U$2.032.284,77, as with reagent
strips for monitoring blood glucose level was U$6.978.321,99.The total spending on
drugs for the treatment of diabetesmellituswasU$10.353.078,08. It is observed that
the cost of test strips correspond to approximately 67.5% of this value.
CONCLUSIONS: These results demonstrate that the costs of inputs for monitoring
of blood glucose have a significant financial impact on the State diabetes program.
Moreover, they suggest the need for research regarding the reasonableness of the
use of these inputs by patients. Education strategies, such as the pharmaceutical
guidance for patients who perform self-monitoring blood glucose levels, aid in the
proper use of these inputs and can avoid any waste.
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OBJECTIVES: To assess the cost of various market share scenarios of leading re-
combinant human growth hormone (rhGH) pens to a commercial health plan,
taking into consideration drug and wastage costs due to device design.METHODS:
A budget impact model (BIM) was developed to determine the costs of rhGH prod-
ucts. Key model inputs included plan size, number of pediatric and adult patients,
mean [SD] weight, product dosing increments and annual wastage due to pen
devices having varying dosing increments. The BIM included storage and reconsti-
tution wastage as an option. Pediatric (n900) and adult (n100) patient weights
were assumed to be normally distributed with mean (SD) 30.25 (4.00) and 75.00
(2.00) kg. Assumed base case dosages were 0.03 mg/kg daily for pediatric patients;
brand-specific based on product package inserts for adult patients. Market share
was indexed at Year 1 (2011) and presented with 10%, 15% and 20% shifts to Nor-
ditropin from Genotropin, Humatrope, and Nutropin. Costs were based onWAC in
US dollars. RESULTS: Costs per patient per year (PPPY) were higher for Genotropin,
Humatrope and Nutropin vs. Norditropin ranging from approximately $23.1K to
$24.6K in pediatrics and $8.1 K to $9.2K in adults. Norditropin was associated with
the lowest annual milligrams of wastage (9.1 mg pediatric/ 8.5 mg adult, including
wastage due to storage and reconstitution) across all pen dosages, followed by
Nutropin (20.7 mg/ 19.9 mg), Humatrope (20.7 mg/20.2 mg) and Genotropin (30.6
mg/ 30.3 mg). Norditropin remained the least costly per year when: dosing from
package inserts was used, adult dosing was fixed, and when storage and reconsti-
tutionwastage was not included. CONCLUSIONS:Due to differences in cost permg
and wastage associated with design among the leading GH brands on the market,
use of Norditropin pens may result in cost savings.
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OBJECTIVES: Central precocious puberty (CPP) is generally treated with gonadotro-
pin releasing hormone (GnRH) agonists. The objective was to compare the costs of
first year treatment of monthly leuprolide acetate injections and once-a-year his-
trelin acetate implants. METHODS: Two retrospective cohort studies were con-
ducted using datasets derived from the Thomas Reuter’s MarketScan©Multi-State
Medicaid Database (2003-2007) and the MarketScan© Commercial Database (2005-
2009). Inclusion criteria were 2 claims with target diagnoses occurring 30 or more
days apart, enrollment for 3 months before first treatment, and continuous en-
rollment for 12 months after first treatment. A probabilistic patient flow model
was developed using estimates for treatment patterns and costs for products, office
visits, and monitoring therapy. RESULTS: A total of 4802 Medicaid and 7391 Com-
mercial beneficiaries age 12 years or younger were identified as diagnosed with
CPP. 323 Medicaid and 383 Commercial beneficiaries met the inclusion criteria and
were treated with leuprolide for 365 days or more. Medicaid and Commercial pa-
tients compliant with leuprolide (13 treatments/year) had an average of 14.8 and
14.0 treatments, respectively. Fifty-three percent of Medicaid and 54% of Commer-
cial patients were non-compliant and averaged 9.2 and 7.7 treatments, respec-
tively. Cost for treating 100 patients were simulated using existing levels of non-
compliance and an assumption that all patients should be compliant. Based on
current levels of non-compliance, costs for histrelin implants were 1.9% lower in
Medicaid and 6.5% higher in Commercial plans–however, when based on full com-
pliance, costs for histrelin implants were 12.9% lower in Medicaid and 12.1% lower
in Commercial plans. CONCLUSIONS:With current levels of non-compliance with
GnRH agonists, costs for CPP treatment is similar in Medicaid and slightly less
A175V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
expensive with leuprolide in Commercial plans. If full compliance is achieved, cost
of treatment is lower with histrelin implants in bothmarkets. The additional med-
ical cost of non-compliance was not included in this model.
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OBJECTIVES: We sought to evaluate the impact of diabetes prevention costs and
effectiveness on the projected return on investment (ROI) from the perspectives of
a US health care payer and a large, self-insured employer using an improved risk
stratification tool. METHODS: A model comprised of a closed cohort with four
Markov health-states was developed to project diabetes-specific costs and offsets
due to incident diabetes and utilization of prevention resources. Subjects identified
as “at-risk” for diabetes in an annual health risk appraisal would be tested and
stratified into high or moderate-to-low risk groups. Parameters of the screen for
at-risk subjects were based upon published impaired fasting plasma glucose prev-
alence of an insured US population. High risk subjects optionally enter a diabetes
prevention program. Parameters for the risk stratification test were based upon
published data for a multiple biomarker risk assessment test (PreDx DRS). Cost
inputs included direct and indirect medical costs of diabetes and pre-diabetes, and
the cost of stratification testing ($250). A range of intervention costs and effective-
nesswere examined.Model outputs included projected costs, savings, and number
of life years and diabetes-free years saved. RESULTS: At a published annual pre-
vention program cost of $850 and intervention effectiveness of 58%, employers
would see a positive ROI by year 2 that increases through year 5. Savings at year 5
represent a return of $1.71 for every $1 spent on diabetes prevention, with 167
diabetes cases prevented, 547 diabetes-free years and 6.3 life years saved per 10,000
employees. Payers could achieve cost savings at lower program costs and/or in-
creased effectiveness. The ROI depends strongly on reported intervention effec-
tiveness in the range of 31%-72% and is moderately sensitive to cost variations.
CONCLUSIONS: Cost savings for employers and payers are possible using risk
stratification in conjunction with an effective prevention program to reduce dia-
betes incidence.
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OBJECTIVES: Hypervolemic hyponatremia (HN) is commonly found in patients
with decompensated cirrhosis and is associated with increasedmortality, morbid-
ity and longer hospital stays. Despite its prevalence in hospitalized patients (15-
30%), little is known of the effect of HN on cirrhotic patients in terms of resource
utilization. The present study was designed to explore the impact of HN on cost,
length of stay (LOS), ICU admission and 30, 90, 180-day readmission in hospitalized
cirrhotic patients.METHODS: The Premier hospital database was utilized to iden-
tify US hospital inpatients discharged between January 1, 2007 and June 30, 2009.
Hyponatremic cirrhotic patients were identified using primary or secondary ICD-
9-CM codes and were matched to a control group using exact matching on age,
gender, provider region and MS-DRG assignment. Matching was further refined
using propensity scores based on additional patient and hospital covariates. The
final analytic sample contained 3,765 cirrhotic hyponatremia patients and 25,549
cirrhotic non-hyponatremia patients. Cost was analyzed using gamma regression,
LOS with negative binomial regression. ICU admission and hospital readmission
were analyzed using multivariate logistic regression. RESULTS: In contrast to non-
hyponatremic cirrhotic patients, hyponatremic patients with cirrhosis had signif-
icantly higher total inpatient cost (80.56%, CI61.95-101.31; p0.0001), ICU cost
(64.36%; CI38.51-95.01; p.0001), total LOS (63.10%, CI52.96-73.92; p0.0001),
and ICU LOS (62.39%, CI40.26-88.02; p.0001). Hyponatremic cirrhotic patients
were significantly more likely to be admitted to the ICU (OR2.10; p0.0001) and
readmitted at 30- (OR1.38; p0.0003), 90- (OR1.26; p0.0025), and 180-days
(OR1.25; p0.0026) in comparison with non-hyponatremic cirrhotic patients.
CONCLUSIONS: The presence of HN in hospitalized cirrhotic patients is signifi-
cantly associated with increased total and ICU cost and LOS, likelihood of ICU
admission and 30, 90, 180-day readmission.
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OBJECTIVES: A common challenge in the management of type 2 diabetes is to
achieve glycemic control while avoiding side effects, such as weight gain and hy-
poglycemia. Assessing the cost of achieving a clinically relevant composite end-
point of HbA1c7%, no weight gain, and no hypoglycemia may be useful for eval-
uation and comparison of diabetes treatments. The objective of this study is to
estimate the cost per successfully treated patient, to this composite endpoint,
when treated with either liraglutide 1.8mg once-daily or exenatide 10g
twice-daily. METHODS: A recently conducted meta-analysis (Zinman et al. 2012)
estimated the percentage of patients achieving the composite endpoint of
HbA1c7%, no weight gain and no hypoglycemia for liraglutide versus comparator
therapies and placebo. The cost per successfully treated patient for liraglutide
1.8mg and exenatide 10g was calculated as the total acquisition costs over 26
weeks (incl. cost of needles) divided by the percentage of patients reaching the
composite endpoint. RESULTS: After 26 weeks, 40% of patients treated with lira-
glutide 1.8mg (n1,513) were estimated to reach the clinically relevant triple com-
posite endpoint versus 25% when treated with exenatide 10g (n186) (p0.001).
Over 26weeks the calculated costs per successfully treated patientwere lowerwith
liraglutide 1.8mg once-daily ($6641) than exenatide 10g twice-daily ($7535).
CONCLUSIONS:When relating the cost of treatment directly to a clinically relevant
composite outcome, as defined by the percentage of patients reaching an HbA1c
target below 7%, noweight gain and no hypoglycemia, liraglutide 1.8mg once-daily
showed lower costs per successfully treated patient than exenatide 10g twice-
daily, over a 26-week period.
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OBJECTIVES: To assess real-world outcomes among US employees with type 2
diabetes mellitus (T2DM) initiating insulin therapy via insulin glargine (GLA) or
NPH insulin.METHODS: This retrospective analysis used MarketScan® databases
to identify employeeswith T2DMwho initiated GLA or NPH, had continuous health
plan and short-term-disability (STD) coverage for 3-month pre- (baseline) and
1-year post-initiation (follow-up), were insulin-naïve but received 1 oral anti-
diabetes drug (OAD) and/or glucagon-like peptide-1 during baseline period. End-
points included 1-year treatment persistence (continuous study drug use without
discontinuation) and adherence (adjusted medication possession ratio), hypogly-
cemia, healthcare utilization and costs, STDand associated cost. Observed baseline
selection bias between these two cohorts was addressed by 2:1 propensity score
matching (PSM). RESULTS: A total of 534 patients (GLA: 356, NPH: 178) were
matched and analyzed (women 43.8%; baseline mean age 49 year; hospitalization
15.3%; # of OADs 1.8; STD: 3.0 days). During follow-up, patients receiving GLA,
comparing to NPH, were significantly more persistent and adherent (both P0.05),
had lower rates of hospitalization (23.0% vs. 31.4%; P0.036) and endocrinologist
visits (19.1% vs. 26.9%; P0.038), similar hypoglycemia-related event rates (both
4.4%; P1.0), higher diabetes drug costs ($1,915 vs. $1,442; P0.001) but similar total
overall healthcare costs ($13,822 vs. $15,170; P0.488) and total diabetes-related
health care costs ($4,474 vs $5,235; P0.466). STD days and associated cost were
marginally lower for GLA than NPH (16.0 vs. 24.5 days, $2,680 vs. $4,118; both
P0.086). Sensitivity analyses using 1:1 and 3:1 PSM yielded consistent results.
CONCLUSIONS: This study suggested that among US employees with T2DM
initiating insulin, compared to NPH, GLA was associated with improved persis-
tence and adherence and similar direct health care cost despite higher drug
costs. GLA was also associated with lower hospitalization rate, which further
led to shorter STD days and associated cost, and might help improve workplace
productivity.
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OBJECTIVES: Randomized clinical trials, SALT-1 and SALT-2, showed that tolvap-
tan was an efficacious and safe therapy for the treatment of hyponatremic SIADH
(Syndrome of Inappropriate Antidiuretic Hormone Secretion) and was associated
with a reduction in the length of stay (LOS) in the hospital for SIADH patients. This
study evaluated the medical cost offsets associated with tolvaptan usage based on
the SALT-1 and SALT-2 trials.METHODS: The Healthcare Cost and Utilization Proj-
ect (HCUP) 2009 Nationwide Inpatient Sample (NIS) database was used to estimate
LOS and hospital cost of SIADH patients (age18 years) in the United States. A cost
offset model was constructed and utilized to evaluate the impact of tolvaptan on
hospital cost and LOS, with univariate and multivariate Monte Carlo sensitivity
analyses. RESULTS: In the SALT-1 and SALT-2 trials, SIADH patients receiving
tolvaptan had a shorter hospital LOS than placebo patients (4.98 vs. 6.19 days).
From the HCUPNIS database, 21,718 SIADH hospitalizationswere identified, with a
mean LOS of 5.7 days andmeanhospital costs of $8667.With an inpatient tolvaptan
treatment duration of 4 days, the cost offset model estimated that tolvaptan usage
was associated with amean LOS reduction of 1.1 days and a hospital cost saving of
$694 per admission. The cost reduction ranged from $355 to $1033 with variations
of any singlemodeling parameter. 10,000 cycles of Monte Carlo simulation showed
the 95% confidence interval for cost saving to be $73$1,405, with 98.8% cycles
having a positive net cost saving. The total cost saving was estimated to be $15
million among the HCUP/SIADH population. CONCLUSIONS: Based on the SALT-1
and SALT-2 trials, tolvaptan usage versus placebo is associated with a shorter
hospital LOS. This study showed that tolvaptan usage versus placebo is addition-
ally associated with lower hospital costs among hyponatremic SIADH patients in
the United States.
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